Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SYK
SYK logo

SYK Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
309.080
Open
307.500
VWAP
306.06
Vol
6.07M
Mkt Cap
116.96B
Low
304.000
Amount
1.86B
EV/EBITDA(TTM)
18.51
Total Shares
383.36M
EV
129.69B
EV/OCF(TTM)
24.13
P/S(TTM)
4.71
Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease.
Show More

Events Timeline

(ET)
2026-05-26
06:20:00
Stryker Launches Pangea Plating System in Europe
select

News

Newsfilter
7.0
05-26Newsfilter
Iranian Hackers Disrupt Los Angeles Transit System
  • Cyber Attack Incident: Israeli researchers have identified that Iranian hackers executed a disruptive cyberattack on the Los Angeles County Metropolitan Transportation Authority (LACMTA) in March, stealing at least 700GB of emails and backup files, which led to parts of the network being shut down, although train and bus operations remained unaffected, customer service was disrupted.
  • Hacker Group Background: The hacker group known as Ababil claimed responsibility for the attack, with its name referencing a bombing incident in the Iranian city of Minab, raising suspicions of its potential ties to the Iranian state and reinforcing the view of it as a proxy for Iranian espionage.
  • Investigation and Response: Gambit Security, a cybersecurity firm, has alerted relevant authorities about its findings, while the FBI stated it is coordinating a response to the incident, although the Los Angeles transit authority has not commented on the investigation's results.
  • Ongoing Cyber Threats: Since the onset of the U.S. and Israel's war against Iran in late February, Iranian hackers have been launching frequent cyberattacks across various sectors, including medical devices and infrastructure, indicating a sustained enhancement of their cyber capabilities and a significant threat to critical infrastructure.
Newsfilter
5.0
05-26Newsfilter
Stryker Launches Pangea Plating System in Europe
  • European Launch: Stryker's introduction of the Pangea Plating System in Europe aims to treat a wide range of fracture patterns, marking a significant expansion in the trauma care sector that is expected to enhance market share and brand influence.
  • Successful Clinical Application: Prof. Alex Trompeter and his team at St. George's University Hospital in London completed the first clinical case in Europe, demonstrating the system's effectiveness in real surgical settings and validating its practical design philosophy.
  • Global Collaborative Development: The Pangea portfolio was developed in collaboration with 26 orthopedic surgeons worldwide, incorporating global anatomical data to ensure applicability across diverse patient populations, thereby enhancing surgical flexibility and efficiency.
  • Surgical Workflow Optimization: The system is designed to simplify operating room procedures and adapt to various fracture patterns, which is expected to improve surgeons' workflows and enhance patient treatment outcomes.
CNBC
8.0
05-19CNBC
Seeking Stable Dividend Growth Amid Market Turbulence
  • Dividend Growth Strategy: Trivariate Research emphasizes that in turbulent markets, investors should focus on companies with consistent dividend growth over the past five years for downside protection, especially as traditional defensive stocks now represent just over 10% of the S&P 500's market cap.
  • Rollins Performance: Pest control company Rollins recently raised its dividend by over 10% to 18 cents per share, and despite a roughly 10% decline in its stock in 2026, analysts remain optimistic about its ability to deliver compounding growth, with Goldman Sachs reiterating a buy rating.
  • Cheniere Energy Growth: Liquefied natural gas company Cheniere Energy increased its quarterly dividend by over 10% last October, currently yielding 0.9%, and its stock has risen 26% this year, benefiting from reduced LNG production in the Middle East.
  • Analyst Support: Cheniere Energy's first-quarter results exceeded expectations, raising its adjusted EBITDA guidance to between $7.25 billion and $7.75 billion, with analysts bullish on its strong volume outlook and project execution, as 23 out of 24 analysts rate it a buy.
seekingalpha
8.5
05-19seekingalpha
Stryker Acquires Amplitude Vascular for Up to $835M
  • Acquisition Scale: Stryker's acquisition of Amplitude Vascular Systems for up to $835 million marks a significant milestone in expanding its peripheral vascular portfolio, expected to enhance its market position in treating calcified peripheral arterial disease.
  • Technological Innovation: Amplitude's next-generation hydraulic intravascular lithotripsy platform offers a new solution for treating calcified peripheral arterial disease, potentially improving patient outcomes and strengthening Stryker's competitive edge in the medical technology sector.
  • Strategic Partnership Background: Venture capital firm BioStar Capital served as an early strategic growth partner for Amplitude, providing IP licensing, initial startup capital, and guidance through various development phases and clinical studies, showcasing a robust support network for the startup.
  • Future Outlook: Despite recent cyber incidents, Stryker maintains its 2026 outlook of 8%-9.5% organic sales growth and adjusted EPS of $14.90-$15.10, indicating confidence in future growth and adaptability in the market.
Newsfilter
8.5
05-19Newsfilter
BioStar Capital Achieves Landmark Exit in Cardiovascular Technology
  • Technological Innovation: Amplitude Vascular Systems (AVS) has developed a next-generation hydraulic lithotripsy technology that offers a new alternative for treating calcified peripheral artery disease, potentially reducing the annual treatment costs of approximately $100 billion significantly.
  • Strategic Acquisition: Stryker's acquisition of AVS for up to $835 million marks a milestone in expanding its peripheral vascular portfolio, further solidifying its leadership position in the medical technology sector.
  • Local Roots: All three companies have strong ties to Michigan, with BioStar Capital's founder, Louis Cannon, first encountering hydraulic lithotripsy technology while serving on the University of Michigan's Coulter Committee, which propelled the technology's development.
  • Successful Exit: This acquisition represents the latest successful exit for BioStar Capital, which has previously invested in several medical technology firms, including Corindus Vascular Robotics, acquired by Siemens for $1.1 billion.
CNBC
4.5
05-11CNBC
Market Punishes Stocks More Aggressively, Tech Stocks Favored
  • Increased Market Punishment: Jim Cramer highlights that the current market punishes companies that miss expectations more severely than in 1999, with Abbott Laboratories down 34% this year, indicating a strong aversion to non-tech stocks.
  • Investor Sentiment Divergence: While the S&P 500 and Nasdaq Composite reached record highs, Cramer warns of a pronounced market bifurcation where investors flock to a narrow group of AI winners while aggressively selling off other companies.
  • Healthcare Sector Struggles: Cramer notes that companies like Danaher have seen stock declines of 27% due to poor performance, with Boston Scientific and Intuitive Surgical also hitting new lows, reflecting a lack of confidence in the healthcare sector.
  • Dot-Com Bubble Comparisons: Cramer cautions against direct comparisons to the dot-com era, arguing that current market dynamics are more extreme, with some hated stocks being excessively punished while loved stocks are excessively favored, creating a stark market polarization.
Wall Street analysts forecast SYK stock price to rise
20 Analyst Rating
Wall Street analysts forecast SYK stock price to rise
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
390.00
Averages
430.32
High
465.00
Current: 0.000
sliders
Low
390.00
Averages
430.32
High
465.00
Truist
Richard Newitter
Hold
downgrade
$380 -> $330
AI Analysis
2026-05-04
Reason
Truist
Richard Newitter
Price Target
$380 -> $330
AI Analysis
2026-05-04
downgrade
Hold
Reason
Truist analyst Richard Newitter lowered the firm's price target on Stryker to $330 from $380 and keeps a Hold rating on the shares. The firm is adjusting its model following the company's Q1 results, also noting that Stryker's cadence of earnings has shifted due to Q1 cyber-attack disruption. Truist adds that its price target cut is based on the lower multiple stemming from multiple compression within the large-cap MedTech peer group, the analyst tells investors in a research note.
Barclays
Matt Miksic
Overweight
downgrade
$469 -> $394
2026-05-04
Reason
Barclays
Matt Miksic
Price Target
$469 -> $394
2026-05-04
downgrade
Overweight
Reason
Barclays analyst Matt Miksic lowered the firm's price target on Stryker to $394 from $469 and keeps an Overweight rating on the shares. The company's Q1 results were mixed and below Street estimates, the analyst tells investors in a research note. The firm cites the "significant back-end loaded ramp required" to achieve Stryker's full year guidance for the target cut.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SYK
Unlock Now

Valuation Metrics

The current forward P/E ratio for Stryker Corp (SYK.N) is 20.41, compared to its 5-year average forward P/E of 26.14. For a more detailed relative valuation and DCF analysis to assess Stryker Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
26.14
Current PE
20.41
Overvalued PE
28.47
Undervalued PE
23.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
21.34
Current EV/EBITDA
19.75
Overvalued EV/EBITDA
23.11
Undervalued EV/EBITDA
19.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.27
Current PS
3.97
Overvalued PS
5.83
Undervalued PS
4.70

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

which stocks will decrease this week
Intellectia · 42 candidates
Region: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossDownMA5, PriceBelowMA20Week Price Change Pct: $-100.00 - $-2.00One Week Rise Prob: 0 - 40One Week Predict Return: -100.0% - -2.0%
Ticker
Name
Market Cap$
top bottom
SYK logo
SYK
Stryker Corp
125.81B
VTR logo
VTR
Ventas Inc
39.03B
VEEV logo
VEEV
Veeva Systems Inc
29.25B
RYTM logo
RYTM
Rhythm Pharmaceuticals Inc
5.64B
DBX logo
DBX
Dropbox Inc
5.58B
CRSP logo
CRSP
CRISPR Therapeutics AG
4.46B
top stocks in health sector
Intellectia · 38 candidates
Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
866.87B
ABBV logo
ABBV
AbbVie Inc
364.65B
AZN logo
AZN
AstraZeneca PLC
293.00B
MRK logo
MRK
Merck & Co Inc
282.35B
UNH logo
UNH
UnitedHealth Group Inc
254.55B
AMGN logo
AMGN
Amgen Inc
188.63B
ok the us stocks instead
Intellectia · 197 candidates
Price: >= $5.00Market Cap Category: large, mid, smallGross Margin: >= 20.00Net Margin: >= 5.00Debt Equity: <= 150List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Annual Eps Yoy Growth: >= 5.0%Annual Revenue Yoy Growth: >= 5.0%
Ticker
Name
Market Cap$
top bottom
KLAC logo
KLAC
KLA Corp
199.83B
CRM logo
CRM
Salesforce Inc
182.52B
APH logo
APH
Amphenol Corp
179.54B
SCCO logo
SCCO
Southern Copper Corp
178.81B
SCHW logo
SCHW
Charles Schwab Corp
166.81B
SYK logo
SYK
Stryker Corp
148.28B
which stock to pick tomorrow
Intellectia · 158 candidates
Relative Vol: >= 1.15Weekly Average Turnover: >= 1,000,000Moving Average Relationship: PriceAboveMA5Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
1.02T
AMD logo
AMD
Advanced Micro Devices Inc
406.68B
CAT logo
CAT
Caterpillar Inc
302.02B
AMGN logo
AMGN
Amgen Inc
185.02B
SYK logo
SYK
Stryker Corp
138.80B
ETN logo
ETN
Eaton Corporation PLC
131.26B
which stock to buy for this week earnings
Intellectia · 213 candidates
Market Cap: >= 1000.00MBeta: LowRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True
Ticker
Name
Market Cap$
top bottom
MCD logo
MCD
McDonald's Corp
217.70B
SHEL logo
SHEL
Shell PLC
209.17B
AMGN logo
AMGN
Amgen Inc
185.02B
SPGI logo
SPGI
S&P Global Inc
160.84B
PFE logo
PFE
Pfizer Inc
147.20B
SYK logo
SYK
Stryker Corp
138.80B
strong buy stocks today
Intellectia · 61 candidates
Analyst Consensus: Strong BuyWeekly Average Turnover: >= 1,000,000Rsi 14: 30 - 70Week Price Change Pct: >= $0.00Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.45T
LLY logo
LLY
Eli Lilly and Co
1.02T
UNH logo
UNH
UnitedHealth Group Inc
315.01B
KO logo
KO
Coca-Cola Co
309.76B
TMO logo
TMO
Thermo Fisher Scientific Inc
239.06B
C logo
C
Citigroup Inc
198.97B
Stocks that trade in a channel
Intellectia · 222 candidates
Beta: LowRiskWeekly Average Turnover: >= 1,000,000Moving Average Relationship: PriceAboveMA20Support Resistance Relationship: PriceAroundResistance, PriceAroundSupport
Ticker
Name
Market Cap$
top bottom
WMT logo
WMT
Walmart Inc
951.32B
BABA logo
BABA
Alibaba Group Holding Ltd
402.68B
CVX logo
CVX
Chevron Corp
335.71B
UNH logo
UNH
UnitedHealth Group Inc
315.01B
NVS logo
NVS
Novartis AG
278.44B
MRK logo
MRK
Merck & Co Inc
275.78B

Whales Holding SYK

P
Pallas Capital Advisors LLC
Holding
SYK
+28.68%
3M Return
A
Alecta Pensionsförsäkring, ömsesidigt
Holding
SYK
+20.62%
3M Return
A
Argenta Asset Management SA
Holding
SYK
+20.17%
3M Return
T
T. Rowe Price Group, Inc.
Holding
SYK
+17.21%
3M Return
O
Oak Ridge Investments, LLC
Holding
SYK
+17.06%
3M Return
F
F. L. Putnam Investment Management Company
Holding
SYK
+16.76%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Stryker Corp (SYK) stock price today?

The current price of SYK is 305.09 USD — it has decreased -0.83

What is Stryker Corp (SYK)'s business?

Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease.

What is the price predicton of SYK Stock?

Wall Street analysts forecast SYK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SYK is430.32 USD with a low forecast of 390.00 USD and a high forecast of 465.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Stryker Corp (SYK)'s revenue for the last quarter?

Stryker Corp revenue for the last quarter amounts to 6.02B USD, increased 2.63

What is Stryker Corp (SYK)'s earnings per share (EPS) for the last quarter?

Stryker Corp. EPS for the last quarter amounts to 1.93 USD, increased 14.20

How many employees does Stryker Corp (SYK). have?

Stryker Corp (SYK) has 56000 emplpoyees as of May 31 2026.

What is Stryker Corp (SYK) market cap?

Today SYK has the market capitalization of 116.96B USD.